Cargando…
Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
DS-7423, a novel, small-molecule dual inhibitor of phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), is currently in phase I clinical trials for solid tumors. Although DS-7423 potently inhibits PI3Kα (IC(50) = 15.6 nM) and mTOR (IC(50) = 34.9 nM), it also inhibits other...
Autores principales: | Kashiyama, Tomoko, Oda, Katsutoshi, Ikeda, Yuji, Shiose, Yoshinobu, Hirota, Yasuhide, Inaba, Kanako, Makii, Chinami, Kurikawa, Reiko, Miyasaka, Aki, Koso, Takahiro, Fukuda, Tomohiko, Tanikawa, Michihiro, Shoji, Keiko, Sone, Kenbun, Arimoto, Takahide, Wada-Hiraike, Osamu, Kawana, Kei, Nakagawa, Shunsuke, Matsuda, Koichi, McCormick, Frank, Aburatani, Hiroyuki, Yano, Tetsu, Osuga, Yutaka, Fujii, Tomoyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913610/ https://www.ncbi.nlm.nih.gov/pubmed/24504419 http://dx.doi.org/10.1371/journal.pone.0087220 |
Ejemplares similares
-
Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells
por: Fukuda, Tomohiko, et al.
Publicado: (2016) -
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging
por: Inaba, Kanako, et al.
Publicado: (2016) -
Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas
por: Uehara, Yuriko, et al.
Publicado: (2015) -
Correction: Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas
por: Uehara, Yuriko, et al.
Publicado: (2015) -
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53
por: Makii, Chinami, et al.
Publicado: (2016)